Citations

Clear

213 citation(s) found for "Lloyd, R".

Relationship Between Degree of Stenosis and Time-to-Peak Delay in High Grade Asymptomatic Carotid Artery Disease
Marshall, Randolph S. , Lal, Brajesh K. , Edwards, Lloyd J. , Huston, John, Meschia, James F., Brott, Thomas G. , Howard, George , Mena-Hurtado, Carlos I., Heck, D , Sangha, Navdeep , Lanzino, Giuseppe, Sharafuddin, Mel, Jumani, Shariq, Voeks, Jenifer H. , Zhang, Yu, Slane, Kevin J., Lazar, Ronald M. , Liebeskind, David S., investigators, on behalf of the POSA trial, Meschia, James F. , Huston, John , Liebeskind, David S. , Mena‐Hurtado, Carlos , Edwards, Lloyd J. , Huston, John , Meschia, James F , Mena-Hurtado, Carlos , Lanzino, Giuseppe , Kashyap, Vikram S , Aronow, Herbert D , Sharafuddin, Mel , Jumani, Shariq , Lazar, Ronald M , Liebeskind, David S. , Howard, George , Marshall, Randolph S. , Lanzino, Giuseppe , Kashyap, Vikram S. , Aronow, Herbert D. , Rai, Pranjal , Slane, Kevin

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: 4 | Pages: 992-999

10.1161/strokeaha.125.054149 | PMID 41608800 Get It

BACKGROUND: Cerebral hemodynamic impairment in patients with asymptomatic high-grade (>70%) internal carotid artery (ICA) stenosis is associated with risk of stroke and cognitive decline, but correlations between the degree of stenosis and hemodynamic impairment are derived from small case series. Using baseline data from 242 participants in the CREST-H study (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis–Hemodynamics), we hypothesized that the degree of stenosis in the ICA would correlate with time-to-peak (TTP) delay in ipsilateral cerebral blood flow using MR/CT perfusion scans, adjusting for demographic and cardiovascular risk variables. METHODS: From all participants, ICAs were insonated using a 7 to 10 MHz probe for peak systolic velocity (PSV) and end diastolic velocity. Dynamic contrast perfusion imaging was standardized across 61 CREST-H sites, using standard sequential T2*-weighted perfusion imaging. CT perfusion used standard clinical protocols. TTP delay was calculated in the ipsilateral versus contralateral hemispheres. In cross-sectional analysis, linear regression was used to model TTP delay as the outcome variable and PSV, end diastolic velocity, and PSV ICA/common carotid artery ratio on the index and nonindex side as primary predictor variables in 6 separate models, adjusting for covariates, followed by automated backward elimination model reduction. RESULTS: Among 392 CREST-H participants, the 242 with complete data for all variables were included in the regression analysis (age, 70±7.6; 62% M). End diastolic velocity on the index side correlated with TTP delay (β=0.003, P =0.005). PSV had a similar correlation but did not reach significance (β=0.001, P =0.099), nor did ICA/common carotid artery ratio (β=0.003, P =0.126). Nonindex side PSV, end diastolic velocity, and ICA/common carotid artery ratio showed no correlation with TTP delay ( P =0.268, P =0.495, P =0.380, respectively). Circle of Willis completeness did not correlate with TTP. CONCLUSIONS: In this large cohort of patients with high-grade asymptomatic carotid stenosis, higher end-diastolic flow velocities correlated with greater TTP delays, supporting a definition of hemodynamically significant stenosis. Our findings have implications for the management of asymptomatic carotid stenosis, which will be tested in the CREST-H study. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03121209.
Sleep-Disordered Breathing in Newborns After Myelomeningocele Repair
Hassan, Fauziya, Mason, Thornton, Anadkat, Jagruti, Bendel‐Stenzel, Ellen , Eyerly-Webb, Stephanie, Jon, Cindy, Lloyd, Robin M. , Moldenhauer, Julie S. , Papanna, Ramesha, Pascoe, John E, Reynolds, Regina , Rocque, B., Simakajornboon, Narong , Treadwell, Marjorie C. , Troxler, R. Bradley, Youmans, Lydia , McCaffery, Harlan, Parmar, Hemant A., Merley, Lora, Rau, S M, Chervin, Ronald D., Barks, JD, Bendel-Stenzel, Ellen, Shellhaas, Renée A. , Anadkat, Jagruti , Eyerly‐Webb, Stephanie A. , Papanna, Ramesha , Pascoe, John E. , Riddle, Stefanie , Troxler, Robert Bradley, Kaciroti, Niko , Rau, Stephanie M. , Chervin, Ronald D.

Mayo Clinic

Pediatrics | January 23, 2026 | Volume: 157 | Issue: 2 | Pages: No page available

10.1542/peds.2025-073458 | PMID 41570998 Get It

BACKGROUND & OBJECTIVE Sleep-disordered breathing (SDB) may be a remediable contributor to abnormal cognitive outcomes for children with myelomeningocele. We investigated the frequency of SDB among neonates with fetal vs postnatal myelomeningocele repair. METHODS In this nine-center, prospective, observational study, neonates with myelomeningocele born at more than 30 weeks gestational age underwent a 10-hour bedside polysomnogram at at least 35 weeks postmenstrual age, before hospital discharge. The primary outcome was SDB severity, reflected by the apnea-hypopnea index (AHI; number of respiratory events per hour of sleep). Decisions regarding surgical timing (fetal vs postnatal), technique (open fetal vs fetoscopic approach), and SDB treatment were made by the clinical teams. RESULTS Among 173 infants, 92/173 (53%) had SDB (median AHI 22.5, IQR 12.2–44.2). In unadjusted analysis, AHI was higher among the 90 neonates with fetal repair vs 83 with postnatal surgery (median 29, IQR 14–49, vs 19, IQR 10–36, P = .008). In propensity-adjusted multivariable models, prematurity was independently associated with AHI, whereas surgical timing (fetal vs postnatal) was not. Hindbrain herniation, myelomeningocele level, and clinical need for ventriculoperitoneal shunt did not predict AHI in adjusted models. Supplemental oxygen was commonly prescribed, for 44% of fetal vs 39% of postnatal myelomeningocele repair infants (P = .5). CONCLUSIONS SDB affects more than half of neonates with myelomeningocele. The higher AHI after fetal surgery could stem from the elevated incidence of prematurity in this group. As SDB is treatable and has a potential impact on neurodevelopment, routine screening could become an integral part of a strategy to optimize long-term medical and neurodevelopmental outcomes.
Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA
Kabarriti, R., Lloyd, Shane , Jabalee, James , Gay, Laurie M. , Slater, T. F., Guzman, Kayleen, Jacobs, Corbin D. , Inocencio, Sean, Lin, Ray , Nguyen, Cammie , MacEwan, Iain, Crawford, Alexandra H., Rutenberg, Michael, Singh, Jaswinder, Ross, Jennifer, Kim-Wang, Sophia Y., Matthiesen, Chance, Neff, Kasha, Liu, Gene-Fu, Juarez, Tiffany , Neff, Kasha , Jacobs, Corbin , Rutenberg, Michael , Neff, Kasha , Juarez, Tiffany M , Lloyd, Shane L , Slater, Tyler, Liauw, Stanley L.

Mayo Clinic

Cancers | December 23, 2025 | Volume: 18 | Issue: 1 | Pages: 35

10.3390/cancers18010035 | PMID 41514548 Get It

Background/Objectives: Surveillance for anal squamous cell carcinoma (ASCC) recurrence relies on clinical examination and imaging. Post-treatment edema, fibrosis, and inflammation can result in clinically indeterminate findings (CIFs) that delay diagnosis and increase patient and system burden. Circulating tumor tissue-modified viral (TTMV)-HPV DNA offers a biologically specific, noninvasive biomarker that may clarify equivocal assessments. Methods: In this multi-center retrospective study, 233 patients with HPV-associated ASCC were evaluated, including 185 with ≥1 post-treatment TTMV-HPV DNA test. CIFs were defined as exams or imaging results not definitively positive or negative for disease, and were paired with subsequent TTMV-HPV DNA tests. Concordance was defined by prespecified follow-up windows comparing TTMV-HPV DNA results with subsequent clinical outcomes. Results: Ninety patients (39%) experienced 214 CIFs, arising from exams (46%, 98) or imaging (54%, 116). Indeterminate rates by assessment were 7% for exams, 17% for imaging, and 1.3% for TTMV-HPV DNA testing. Overall, 52 CIF/TTMV-HPV DNA pairs were eligible for analysis, and TTMV-HPV DNA resolved disease status accurately for 48/52 (92%, 95% CI: 81.5–97.9). Negative tests predicted cancer-free status for 37/41 CIFs (90%), while 100% of positive tests (11/11) were concordant with clinically confirmed recurrence. In 73% of positive cases (8/11), TTMV-HPV DNA was the first indication of recurrence (median lead-time 29 days; IQR 25–147). Conclusions: TTMV-HPV DNA testing reliably clarifies clinically indeterminate findings during ASCC surveillance, demonstrating high accuracy (92%) and earlier detection of recurrence. These data support integration into post-treatment management to reduce diagnostic uncertainty and guide timely care.
One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator
Lloyd, Michael S. , Roberts, Paul R. , Doshi, Rahul N. , Wright, David J. , Boersma, Lucas V.A. , Friedman, Paul A. , Neužil, Petr , Blomström‐Lundqvist, Carina , Bongiorni, M. G. , Burke, Martin C. , Gras, Daniel , Kutalek, Steven , Marijon, Éloi , Amin, Anish K. , Aasbo, Johan D. , West, Julie, Matznick, Elizabeth , Speakman, Benjamin, Bachman, Tara N. , Reddy, Vivek Y , Roberts, Paul , Doshi, Rahul N , Wright, David L , Boersma, Lucas , Friedman, Paul A , Neuzil, Petr , Blomström-Lundqvist, Carina , Bongiorni, Maria Grazia , Burke, Martin C , Gras, Daniel , Kutalek, Steven P , Marijon, Eloi , Tolosana, Jose María , Amin, Anish K , Epstein, Laurence M , Aasbo, Johan D , Callahan, Thomas D , Brisben, Amy J , Matznick, Elizabeth , Bachman, Tara N , Mont, Lluís , Knops, Reinoud Elwin , Reddy, Vivek Y. , Epstein, Laurence M.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 13, 2025 | Volume: 19 | Issue: 1 | Pages: No page available

10.1161/circep.125.014395 | PMID 41231774 Get It

BACKGROUND: MODULAR antitachycardia pacing (ATP), a multicenter, international trial, assesses a modular cardiac rhythm management system: a subcutaneous implantable cardioverter defibrillator in wireless communication with a leadless pacemaker (LP) capable of pace-terminating ventricular tachycardia. METHODS: Enrolees had one or more clinical risk factors for ventricular tachycardia and did not require chronic pacing. Complications included prespecified major LP system- and procedure-related complications, and any complication related to the LP, subcutaneous implantable cardioverter defibrillator, implantation, or study protocol. Survival analysis was performed to identify complication-free rates, therapy delivery, and all-cause mortality. RESULTS: The 297 patients enrolled had an ejection fraction of 35±13%, 43% secondary prevention indications, and 59% with prior ventricular arrhythmias. Of 286 patients undergoing LP implantation (100% success), 251 patients completed 12-month follow-up. Mortality rate was 6%, with none related to the implant procedure. Median follow-up duration was 23.4 months (interquartile range, 17.9–28.1). The LP major complication-free rate was 97.2%, exceeding the performance goal. The overall LP+ subcutaneous implantable cardioverter defibrillator system-related complication-free rate was 88.5%. Appropriate tachyarrhythmia-therapy (ATP+shock) rates were 14.4%, and appropriate shock rates were 8.5%. Inappropriate total tachyarrhythmia therapy was 9.5% of which 8.5% were shocks. ATP was 67.3% successful in terminating ventricular arrhythmia episodes and accelerated ventricular arrhythmias in 10.1% of episodes. Overall therapy burden (ATP+shock) was 96/100 patient-years, of which 44/100 patient-years was for shock delivery. CONCLUSIONS: One-year outcomes of the first modular pacing-defibrillator system reveal low system and LP complication rates and good ATP efficacy rates, suggesting that the modular cardiac rhythm management is a viable alternative to single-chamber implantable cardioverter defibrillators using low-energy pacing capability without the need for transvenous leads. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT04798768.
Radiosurgery for Sporadic Facial Nerve Schwannoma: An International Multi-institutional Study of 60 Cases
Marinelli, John P. , Lloyd, Simon , Steiner, Nejc , Babajanian, Eric E. , Lohse, Christine M. , Sheehan, Jason , Kutz, Joe Walter , Duke, Simon, Link, Michael J., Carlson, Matthew L. , Cottrell, Justin , Borsetto, Daniele , Mantziaris, Georgios , Meng, Ying , Axon, Patrick , Kondziolka, Douglas , Roland, J. Thomas

Mayo Clinic

Otology & Neurotology | November 13, 2025 | Volume: 47 | Issue: 2 | Pages: 350-355

10.1097/mao.0000000000004758 | PMID 41225703 Get It

Objective: To characterize patient outcomes after primary stereotactic radiosurgery (SRS) for the management of sporadic facial nerve schwannoma. Study design: Retrospective cohort study. Setting: Six tertiary referral centers across the United States and United Kingdom. Patients: Adults undergoing SRS from 2000 through 2023 for sporadic facial nerve schwannoma along any segment of the facial nerve were included. Patients with NF2-related schwannomatosis were excluded. Intervention: Stereotactic radiosurgery. Main outcome measure: Long-term tumor control. Results: Among 60 patients meeting inclusion, the median age at SRS was 52 years (IQR: 41 to 64) with a median tumor size of 19.5 mm (IQR: 14.7 to 22.8). Tumors commonly involved the internal auditory canal (73%), cisternal (49%), geniculate/labyrinthine (47%), and tympanic segments (22%). Two patients experienced SRS failure and underwent salvage treatment; salvage-free survival rates (95% CI; number still at risk) at 1, 3, 5, and 10 years after SRS were 100% (100 to 100; 55), 100% (100 to 100; 36), 100% (100 to 100; 18), and 87% (72 to 100; 9), respectively. Among 31 (52%) patients with House-Brackmann (HB) grade I facial function at presentation, only 6 demonstrated worse facial function at a median of 3.2 years (IQR: 1.7 to 6.6) after SRS. Of 18 patients with serviceable hearing (AAO-HNS class A/B) at SRS, 13 maintained serviceable hearing at a median of 1.0 years (IQR: 0.5 to 4.9) of post-SRS audiometric follow-up. Conclusions: Durable tumor control after primary SRS for sporadic facial nerve schwannoma is achieved in most patients. Among those with HB grade I facial function at presentation, treatment with SRS harbors limited additional risk of facial paresis beyond observation alone.
SPIROMICS HF: Rationale, Design, and Reproducibility of Measures
Barr, R. Graham , Lima, João A.C. , Prince, Martin R. , Abraham, Theodore P. , Agarwal, Prachi , Arora, Garima , Balasubramanian, Aparna , Barjaktarević, Igor , Bello, Natalie A. , Carr, James C. , Cooper, Christopher B. , Finn, J. Paul , Freed, Benjamin H. , Hansel, Nadia N. , Hsu, Jeffrey J. , Kitzman, Dalane W. , LaBounty, Troy , Lee, Yoo Jin , Liu, Jing , Lloyd, Steven G. , Markl, Michael , Ortega, Victor E. , Paine, Robert , Peters, Stephen P. , Schroeder, Joyce , Shepshelovich, Daniel , Sun, Yifei , Wells, J. Michael , Wieben, Oliver , Woodruff, Prescott G. , Ambale-Venkatesh, Bharath , Agarwal, Prachi P , Arora, Garima , Balasubramanian, Aparna , Barjaktarevic, Igor , Bello, Natalie A , Bluemke, David A , Budoff, Matthew , Carr, James C , Chaudhuri, Dipayan , Cooper, Christopher B , Couper, David , Finn, J Paul , Freed, Benjamin H , Han, MeiLan King , Hansel, Nadia N , Hsu, Jeffrey J , Kitzman, Dalane W , Krishnan, Jerry A , LaBounty, Troy M , Lee, Yoo Jin , Liu, Jing , Lloyd, Steven G , Mukherjee, Monica , Beussink-Nelson, Lauren , Ohar, Jill , Paine, Robert , Schroeder, Joyce D , Shen, Wei , Sun, Yifei , Vogel-Claussen, Jens , Watson, Karol E. , Wells, J Michael , Wieben, Oliver , Woodruff, Prescott G , Shah, Sanjiv J , Markl, Michael , Barr, R. Graham , Bluemke, David A. , Budoff, Matthew J. , Couper, David , Mukherjee, Monica , Vogel‐Claussen, Jens

Mayo Clinic

Circulation: Heart Failure | November 5, 2025 | Volume: 18 | Issue: 12 | Pages: No page available

10.1161/circheartfailure.125.012833 | PMID 41190426 Get It

BACKGROUND: Although chronic obstructive pulmonary disease (COPD) and heart failure with preserved ejection fraction often coexist with overlapping clinical features, they are usually studied separately. The SPIROMICS HF (Subpopulations and Intermediate Outcome Measures in COPD and Heart Failure Study) is testing hypotheses that new computed tomography emphysema subtypes are associated with specific cardiovascular phenotypes (eg, cor pulmonale , cor pulmonale parvus ), common airway branch variants are associated with right heart dysfunction, and symptomatic tobacco-exposed persons with preserved spirometry have signs of increased left ventricular afterload. METHODS: SPIROMICS is a multicenter observational study of COPD with extensive pulmonary phenotyping of participants with ≥20 pack-years smoking and nonsmoking controls. COPD and COPD severity were defined by standard spirometric criteria and symptomatic tobacco-exposed persons with preserved spirometry by ≥20 pack-years, normal spirometry, and COPD Assessment Test score >10. SPIROMICS HF selected all participants in SPIROMICS visit 5 at major sites. Its comprehensive speckle-tracking echocardiography, which included physiological perturbations of leg raise and low-intensity exercise, was harmonized prospectively with the Multi-Ethnic Study of Atherosclerosis Early Heart Failure and HeartSHARE (Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets) studies. The cardiopulmonary magnetic resonance imaging protocol with gadolinium administration included myocardial fibrosis sequences, pulmonary angiography, time-resolved 3-dimensional cine magnetic resonance imaging (4-dimensional flow) of venous return, and metronome-paced tachypnea to induce dynamic hyperinflation. Coronary artery calcium was assessed on computed tomography scans. The Kansas City Cardiomyopathy Questionnaire was administered. RESULTS: Of the final sample of 753 participants, 57% had COPD (15% mild, 27% moderate, and 15% severe), 18% had symptomatic tobacco-exposed persons with preserved spirometry, 16% were smoking controls, and 8% were nonsmoking controls. Reproducibility of the main measures from speckle-tracking echocardiography (intraclass correlation coefficient, 0.83–0.99), exercise echocardiography (intraclass correlation coefficient, 0.71–0.99) and magnetic resonance imaging (intraclass correlation coefficient, 0.57–0.99) were good-to-excellent, including in severe COPD. CONCLUSIONS: SPIROMICS HF aims to characterize and understand cardiopulmonary interactions in COPD and COPD-related phenotypes to inform targeted treatments for combined cardiopulmonary failure.
An Unbiased Cell‐Culture Selection Yields DNA Aptamers as Novel Senescent Cell‐Specific Reagents
Pearson, Keenan , Jachim, Sarah K. , Wilbanks, Brandon , Prieto, Luis I. , Dugan, Maria , LeBrasseur, Nathan K. , Maher, L. James , Pearson, Keenan S , Doherty, Caroline D, Wilbanks, Brandon A, LeBrasseur, Nathan K , III, Louis James Maher , Wilbanks, Brandon A , Doherty, Caroline Lloyd , Baker, Darren J. , Doherty, Caroline

Mayo Clinic

Aging Cell | September 19, 2025 | Volume: 24 | Issue: 11 | Pages: No page available

10.1111/acel.70245 | PMID 40970817 Get It

ABSTRACT Cellular senescence is an irreversible form of cell‐cycle arrest caused by excessive stress or damage. While various biomarkers of cellular senescence have been proposed, there are currently no universal, stand‐alone indicators of this condition. The field largely relies on the combined detection of multiple biomarkers to differentiate senescent cells from non‐senescent cells. Here we introduce a new approach: unbiased cell culture selections to identify senescent cell‐specific folded DNA aptamers from vast libraries of trillions of random 80‐mer DNAs. Senescent mouse adult fibroblasts and their non‐senescent counterparts were employed for selection. We demonstrate aptamer specificity for senescent mouse cells in culture, identify a form of fibronectin as the molecular target of two selected aptamers, show increased aptamer staining in naturally aged mouse tissues, and demonstrate decreased aptamer staining when p16 expressing cells are removed in a transgenic INK‐ATTAC mouse model. This work demonstrates the value of unbiased cell‐based selections to identify new senescence‐specific DNA reagents.
Quality measures for care of patients with restless legs syndrome: 2025 update after measure maintenance
Lloyd, Robin M. , Crawford, T’Auna, Donald, Ryan, Gray, Diedra D., Junna, Mithri R. , Lewin, Daniel , Revana, Amee , Schutte-Rodin, Sharon, Healy, William J.

Mayo Clinic

Journal of Clinical Sleep Medicine | September 17, 2025 | Volume: 21 | Issue: 12 | Pages: 2205-2211

10.5664/jcsm.11894 | PMID 40958636 Get It

Radiotherapy for Growing Vestibular Schwannomas
Sethi, Mantegh , Gowrishankar, Shravan , Mannion, Richard , Guilfoyle, Mathew R., Buttimore, Juliette , Gamazo, Nicola, Duke, Simon, Jena, Raj, Burton, Katherine , Fornezza, Umberto, Perini, Zeno, Mari, Cristina , Gazzola, Luca, Schouten, Sammy M , Kunst, Henricus P. M. , Bassi, Rohan, MacKeith, Samuel , Whitfield, Gillian , McBain, Catherine , Hotchkies, A , Lloyd, Simon , Obholzer, Rupert , Cheang, Ya Fang Amanda, Thomas, Nick, Barazi, Sinan, Maratos, Eleni, Hassan, Sheila, Tancu, Cornel, Kitchen, Neil , Marinelli, John P. , Carlson, Matthew L., Link, Michael J. , Tysome, James Russell , Donnelly, Neil P. , Axon, Patrick , Bance, Manohar , Jena, Raj, Burton, Katherine, Jefferies, Sarah , Mari, Cristina, Gazzola, Luca , Compter, Inge , Eekers, Daniëlle B. P. , Jeyaretna, Deva Sanjeeva , Colaco, Rovel J. , Shapey, Jonathan , Carlson, Matthew L. , Borsetto, Daniele

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | September 4, 2025 | Volume: 151 | Issue: 10 | Pages: 931

10.1001/jamaoto.2025.1953 | PMID 40906473 Get It

Importance In the literature, there is a lack of data reporting tumor control rates after radiotherapy in actively growing vestibular schwannomas (VS). Data for this rarely studied population are needed. Objective To estimate tumor control rates in radiologically growing VS treated with first-line radiotherapy. Design, Setting, and Participants This international, multicenter cohort study used prospectively collected data from patients with growing unilateral VS treated first-line with radiotherapy between January 2000 and December 2023 from 8 tertiary referral skull base units. The data were analyzed in June 2025. Exposures Radiotherapy as an initial treatment for VS. Main Outcomes and Measures The primary outcome was treatment failure, ie VS growth postradiotherapy, which was predefined as an increase in maximum intracranial tumor diameter (ICTD) of 3 mm or greater within the first 2 years after radiotherapy or 2 mm or greater thereafter. Secondary outcomes were treatment failure based on different definitions of VS growth: (1) an increase in ICTD of 2 mm or greater, (2) an increase in ICTD of 3 mm or greater, and (3) conversion to surgery. Results A total of 1883 patients (975 female individuals [51.8%]; median age at diagnosis, 63 years [IQR, 53-71 years]) were included in the study. Using the primary definition of treatment failure (an increase in ICTD of ≥3 mm within the first 2 years postradiotherapy or ≥2 mm thereafter), the Kaplan-Meier estimate yielded a 10-year tumor control rate of 76.1% (95% CI, 72.7%-79.2%). For secondary outcome definitions, 10-year tumor control rates were 60.1% (95% CI, 57.5%-64.3%) for an ICTD increase of 2 mm or greater, 78.3% (95% CI, 75.0%-81.2%) for an increase of 3 mm or greater, and 92.6% (95% CI, 90.4%-94.3%) for conversion to surgery. Neither pretreatment tumor size nor tumor location (intracanalicular vs extracanalicular) were significantly associated with treatment failure. Conclusions and Relevance The results of this cohort study provide tumor control outcomes for radiologically growing VS treated with radiotherapy using several clinically relevant definitions of growth. By focusing exclusively on this rarely isolated subgroup, the findings offer targeted data to potentially inform treatment expectations and future research.